Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Neurocrit Care. 2019 Aug;31(1):56–65. doi: 10.1007/s12028-019-00671-1

Table 1.

Baseline characteristics of the studied patient population as stratified by the type of anticoagulant used.

All patients VKA-ICH DOAC-ICH
Characteristics (n=102) (n=77) (n=25) P-value
Age, years 79 (71–84) 80 (72–85) 78 (68.5–82) 0.141
Age, >75 years old 70 (68.6) 54 (70.1) 16 (64) 0.623
Female sex 42 (41.2) 33 (42.9) 9 (36.0) 0.643
Weight, kg 82.7 (68.1–113.4) 80.5 (66.5–93.4) 89.0 (73.7–104.9) 0.053
Admission GCS 13 (7–15) 12 (6–15) 14 (10–15) 0.334
Admission NIHSS 13 (4–25) 14 (4–28) 10 (3–22) 0.436
SBP on admission, mmHg 172 (151–203) 173 (148–204) 168 (160–203) 0.966
DBP on admission, mmHg 91 (73–105) 91 (71–103) 89 (75–112) 0.898
Preexisting risk factors
 Hypertension 99 (97.1) 74 (96.1) 25 (100.0) 0.574
 Diabetes 36 (35.3) 26 (33.8) 10 (40.0) 0.633
 Prior stroke or TIA 31 (30.4) 22 (28.6) 9 (36.0) 0.617
 Coronary artery disease 42 (41.2) 33 (42.9) 9 (36.0) 0.643
 Hyperlipidemia 72 (70.6) 51 (66.2) 21 (84.0) 0.129
 Atrial fibrillation 92 (90.2) 67 (87.0) 25 (100.0) 0.114
Preadmission medications
 Statin 70 (68.6) 52 (67.5) 18 (72.0) 0.854
 Antihypertensive 97 (95.1) 73 (94.8) 24 (96.0) 1.000
 Antiglycemic 26 (25.5) 21 (27.3) 5 (20.0) 0.601
 Antiplatelets 41 (40.2) 30 (39.0) 11 (44.0) 0.815
Laboratory data
 Creatinine, mg/dL 0.9 (0.8–1.4) 1.0 (0.8–1.4) 0.94 (0.8–1.2) 0.747
 GFR, ml/min/1.73 m2 63 (45–88) 60 (41–86) 69 (56–93) 0.105
 GFR <30 ml/min/1.73 m2 9 (8.8) 9 (11.7) 0 (0.0) 0.108
 PLT, 103cells/μL 186 (151–233) 187 (149–236) 185 (165–233) 0.481
 Random glucose, mg/dL 138 (109–177) 138 (111–176) 137 (105–192) 0.762
Targeted reversal strategy used 74 (72.5) 72 (93.5) 2 (8.0) <0.001
Any reversal strategy used 89 (87.3) 72 (93.5) 17 (68.0) 0.003
Reversal strategies used
 Vitamin K 67 (65.7) 66 (85.7) 1 (4.0) <0.001
 Fresh frozen plasma 43 (42.2) 43 (55.8) 0 (0.0) <0.001
 Prothrombin complex concentrate 33 (32.4) 18 (23.4) 15 (60.0) 0.001
 Recombinant activated factor VII 43 (42.2) 29 (37.7) 0 (0) <0.001
 Idarucizumab 2 (2.0) 0 (0.0) 2 (8.0) 0.058
Radiological characteristics
 Supratentorial hemorrhage 78 (76.5) 56 (72.7) 22 (82.0) 0.175
 Lobar hemorrhage 47 (46.1) 34 (44.2) 13 (52.0) 0.645
 IVH present 46 (45.1) 35 (45.5) 11 (44) 1.000

Data are n (%) or median (25th–75th quartile); DBP=Diastolic blood pressure; DOAC-ICH=direct oral anticoagulation related intracerebral hemorrhage; GCS=Glasgow coma scale, GFR=Glomerular filtration rate; IVH=intraventricular hemorrhage; PLT=platelet count; SBP=Systolic blood pressure; TIA=transient ischemic attack; VKA-ICH=vitamin K antagonist related intracerebral hemorrhage.